MA34328B1 - Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale - Google Patents

Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Info

Publication number
MA34328B1
MA34328B1 MA35480A MA35480A MA34328B1 MA 34328 B1 MA34328 B1 MA 34328B1 MA 35480 A MA35480 A MA 35480A MA 35480 A MA35480 A MA 35480A MA 34328 B1 MA34328 B1 MA 34328B1
Authority
MA
Morocco
Prior art keywords
therapeutic agent
renal failure
prolonged release
release against
against hypertension
Prior art date
Application number
MA35480A
Other languages
English (en)
Inventor
Takashi Shirakura
Mizuho Tamura
Yoshimasa Takahashi
Ippei Kuwahara
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371556&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34328(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA34328B1 publication Critical patent/MA34328B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA35480A 2010-06-25 2011-06-24 Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale MA34328B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010145056 2010-06-25
PCT/JP2011/064569 WO2011162390A1 (fr) 2010-06-25 2011-06-24 Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Publications (1)

Publication Number Publication Date
MA34328B1 true MA34328B1 (fr) 2013-06-01

Family

ID=45371556

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35480A MA34328B1 (fr) 2010-06-25 2011-06-24 Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale

Country Status (25)

Country Link
US (1) US20130109726A1 (fr)
EP (1) EP2586442A4 (fr)
JP (1) JPWO2011162390A1 (fr)
KR (1) KR20130088755A (fr)
CN (1) CN102958521A (fr)
AR (1) AR082022A1 (fr)
AU (1) AU2011270133B2 (fr)
BR (1) BR112012032543A2 (fr)
CA (1) CA2803163A1 (fr)
CL (1) CL2012003661A1 (fr)
CO (1) CO6660504A2 (fr)
EC (1) ECSP12012352A (fr)
MA (1) MA34328B1 (fr)
MX (1) MX2012015040A (fr)
MY (1) MY160963A (fr)
NZ (1) NZ605516A (fr)
PE (1) PE20130241A1 (fr)
RU (1) RU2013103366A (fr)
SG (1) SG186798A1 (fr)
TN (1) TN2012000568A1 (fr)
TW (1) TW201215389A (fr)
UA (1) UA107716C2 (fr)
UY (1) UY33468A (fr)
WO (1) WO2011162390A1 (fr)
ZA (1) ZA201209388B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101872189B1 (ko) 2010-06-16 2018-06-29 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타제 억제제 또는 크산틴 옥시다제 억제제의 신규한 조절 방출 제형
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
AR089812A1 (es) * 2012-01-27 2014-09-17 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
US6998404B2 (en) * 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
JP5242393B2 (ja) * 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
CA2619744C (fr) * 2005-08-18 2014-09-02 Teijin Pharma Limited Formulation avec fonction de division en doses precises
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
KR101872189B1 (ko) * 2010-06-16 2018-06-29 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타제 억제제 또는 크산틴 옥시다제 억제제의 신규한 조절 방출 제형

Also Published As

Publication number Publication date
ZA201209388B (en) 2013-08-28
NZ605516A (en) 2015-02-27
UA107716C2 (ru) 2015-02-10
RU2013103366A (ru) 2014-07-27
UY33468A (es) 2012-01-31
WO2011162390A1 (fr) 2011-12-29
CN102958521A (zh) 2013-03-06
US20130109726A1 (en) 2013-05-02
AU2011270133B2 (en) 2014-03-20
BR112012032543A2 (pt) 2016-11-22
KR20130088755A (ko) 2013-08-08
CO6660504A2 (es) 2013-04-30
PE20130241A1 (es) 2013-03-04
CL2012003661A1 (es) 2013-04-01
TN2012000568A1 (en) 2014-04-01
SG186798A1 (en) 2013-02-28
JPWO2011162390A1 (ja) 2013-08-22
TW201215389A (en) 2012-04-16
CA2803163A1 (fr) 2011-12-29
MY160963A (en) 2017-03-31
ECSP12012352A (es) 2013-02-28
MX2012015040A (es) 2013-02-07
AR082022A1 (es) 2012-11-07
EP2586442A1 (fr) 2013-05-01
EP2586442A4 (fr) 2014-01-01
AU2011270133A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
NL300891I2 (nl) Lotilaner en zouten daarvan
HUE037639T2 (hu) Pimavanszerin együttes beadása más szerekkel
BRPI0821316A2 (pt) Adaptador antioclusão para cateter
BR112013013308A2 (pt) inalador e unidade articulada
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
BRPI0812209A2 (pt) Partícula de liberação contendo agente de benefício
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0821876A8 (pt) sistemas e métodos para administração de medicação
DK2144905T3 (da) Terapeutiske midler
ZA201004261B (en) Anthelmintic agents and their use
BRPI0907064A2 (pt) "métodos e sistemas"
EP2128154A4 (fr) Composé de benzimidazole et utilisation pharmaceutique de celui-ci
IL236360A0 (en) Inhalable medicine
BRPI0816789A2 (pt) Goji e inflamação
ZA201104539B (en) Enema preparations and their use
BR112013002544A2 (pt) seção de armario e armario
EP2404520A4 (fr) Chaussure avec structure de modelage et de fixation
DE602008002307D1 (de) Kupplungsanordnung und Verbindungsanordnung
BRPI0818598A2 (pt) agentes terapêuticos - 802
SMT201600041B (it) Agenti terapeutici 713
BRPI0807421A2 (pt) Microrganismo recombinante
MA34328B1 (fr) Agent thérapeutique à libération prolongée contre l'hypertension et l'insuffisance rénale
BR112012016199A2 (pt) estrutura de acoplamento e fivela de fricção
DE502008003154D1 (de) Notentriegelung